



chain nodes :
7 8 9 10 11 25 27
ring nodes :
1 2 3 4 5 6 12 13 14 15 16 17 18 19 20 21 22 23
chain bonds :
2-7 5-9 7-17 8-9 8-11 9-10 11-20
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 12-13 12-17 13-14 14-15 15-16 16-17 18-19 18-23 19-20
20-21 21-22 22-23
exact/norm bonds :
2-7 7-17 8-9 9-10
exact bonds :
5-9 8-11 11-20 18-19 18-23 19-20 20-21 21-22 22-23
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 12-13 12-17 13-14 14-15 15-16 16-17
isolated ring systems :
containing 1 : 12 : 18 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS 11:CLASS
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom
22:Atom 23:Atom 25:CLASS 26:Atom 27:CLASS 28:Atom

=>
Uploading C:\Program Files\Stnexp\Queries\11444444.str



chain nodes :
7 8 9 10 11 25 27
ring nodes :
1 2 3 4 5 6 12 13 14 15 16 17 18 19 20 21 22 23
chain bonds :
2-7 5-9 7-17 8-9 8-11 9-10 11-20
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 12-13 12-17 13-14 14-15 15-16 16-17 18-19
18-23 19-20 20-21 21-22 22-23
exact/norm bonds :
2-7 7-17 8-9 9-10
exact bonds :
5-9 8-11 11-20 18-19 18-23 19-20 20-21 21-22 22-23
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 12-13 12-17 13-14 14-15 15-16 16-17
isolated ring systems :
containing 1 : 12 : 18 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 25:CLASS 26:Atom 27:CLASS 28:Atom

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam
SAMPLE SEARCH INITIATED 18:10:53 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 4 TO ITERATE

```
100.0% PROCESSED        4 ITERATIONS                                3 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            4 TO      200
PROJECTED ANSWERS:               3 TO      163

L2            3 SEA SSS SAM L1

=> => s l1 sss ful
FULL SEARCH INITIATED 18:11:26 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       80 TO ITERATE

100.0% PROCESSED       80 ITERATIONS                               51 ANSWERS
SEARCH TIME: 00.00.01

L3           51 SEA SSS FUL L1

=> => s l3
L4            8 L3

=> d l4 1-8 bib,ab,hitstr
```

L4 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2008:939273 CAPLUS
TI Discovery and Optimization of a Novel Series of N-Arylamide Oxadiazoles as Potent, Highly Selective and Orally Bioavailable Cannabinoid Receptor 2 (CB2) Agonists
AU Cheng, Yuan; Albrecht, Brian K.; Brown, James; Buchanan, John L.; Buckner, William H.; DiMauro, Erin F.; Emkey, Renee; Fremeau, Robert T.; Harmange, Jean-Christophe; Hoffman, Beth J.; Huang, Liyue; Huang, Ming; Lee, Josie Han; Lin, Fen-Fen; Martin, Matthew W.; Nguyen, Hung Q.; Patel, Vinod F.; Tomlinson, Susan A.; White, Ryan D.; Xia, Xiaoyang; Hitchcock, Stephen A.
CS Chemistry Research and Discovery, Department of Molecular Structure, Department of Neuroscience, Department of Protein Science, Amgen Inc., Thousand Oaks, CA, 91320, USA
SO Journal of Medicinal Chemistry (2008), 51(16), 5019-5034
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
AB The CB2 receptor is an attractive therapeutic target for analgesic and anti-inflammatory agents. Herein we describe the discovery of a novel class of oxadiazole derivs. from which potent and selective CB2 agonist leads were developed. Initial hit 7 was identified from a cannabinoid target-biased library generated by virtual screening of sample collections using a pharmacophore model in combination with a series of physicochem. filters. 7 was demonstrated to be a selective CB2 agonist (CB2 EC50 = 93 nM, Emax = 98%, CB1 EC50 > 10 μM). However, this compound exhibited poor solubility and relatively high clearance in rat, resulting in low oral bioavailability. In this paper, we report detailed SAR studies on 7 en route toward improving potency, physicochem. properties, and solubility This effort resulted in identification of 63 that is a potent and selective agonist at CB2 (EC50 = 2 nM, Emax = 110%) with excellent pharmacokinetic properties.
IT 666260-75-9
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GW 842166X; N-arylamide oxadiazoles preparation as selective oral CB2 agonists)
RN 666260-75-9 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2008:324799 CAPLUS
DN 148:486374
TI Arylsulfonamide CB2 receptor agonists: SAR and optimization of CB2 selectivity
AU Ermann, Monika; Riether, Doris; Walker, Edward R.; Mushi, Innocent F.; Jenkins, James E.; Noya-Marino, Beatriz; Brewer, Mark L.; Taylor, Malcolm G.; Amouzegh, Patricia; East, Stephen P.; Dymock, Brian W.; Gemkow, Mark J.; Kahrs, Andreas F.; Ebneth, Andreas; Loebbe, Sabine; O'Shea, Kathy; Shih, Daw-Tsun; Thomson, David
CS Evotec (UK) Ltd., Abingdon, Oxfordshire, OX14 4SA, UK
SO Bioorganic & Medicinal Chemistry Letters (2008), 18(5), 1725-1729
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Ltd.
DT Journal
LA English
OS CASREACT 148:486374
AB A high-throughput screening campaign resulted in the discovery of a highly potent dual cannabinoid receptor 1 (CB1) and 2 (CB2) agonist. Following a thorough SAR exploration, a series of selective CB2 full agonists were identified.
IT 666260-75-9
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GW 842166X; arylsulfonamide CB2 receptor agonists: SAR and optimization of CB2 selectivity)
RN 666260-75-9 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2008:132035 CAPLUS
DN 148:369774
TI In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models
AU Yao, B. B.; Hsieh, G. C.; Frost, J. M.; Fan, Y.; Garrison, T. R.; Daza, A. V.; Grayson, G. K.; Zhu, C. Z.; Pai, M.; Chandran, P.; Salyers, A. K.; Wensink, E. J.; Honore, P.; Sullivan, J. P.; Dart, M. J.; Meyer, M. D.
CS Neurological Diseases Research, Global Pharmaceutical Research & Development, Abbott Laboratories, Abbott Park, IL, 60064, USA
SO British Journal of Pharmacology (2008), 153(2), 390-401
CODEN: BJPCBM; ISSN: 0007-1188
PB Nature Publishing Group
DT Journal
LA English
AB Selective cannabinoid CB2 receptor agonists have demonstrated analgesic activity across multiple preclin. pain models. AM1241 is an indole derivative that exhibits high affinity and selectivity for the CB2 binding site and broad spectrum analgesic activity in rodent models, but is not an antagonist of CB2 in vitro functional assays. Addnl., its analgesic effects are -opioid receptor-dependent. Herein, we describe the in vitro and in vivo pharmacol. properties of A-796260, a novel CB2 agonist. Exptl. approach: A-796260 was characterized in radioligand binding and in vitro functional assays at rat and human CB1 and CB2 receptors. The behavioral profile of A-796260 was assessed in models of inflammatory, post-operative, neuropathic, and osteoarthritic (OA) pain, as well as its effects on motor activity. The receptor specificity was confirmed using selective CB1, CB2, and -opioid receptor antagonists. A-796260 exhibited high affinity and agonist efficacy at human and rat CB2 receptors, and was selective for the CB2 vs CB1 subtype. Efficacy in models of inflammatory, post-operative, neuropathic and OA pain was demonstrated, and these activities were selectively blocked by CB2, but not CB1, or -opioid receptor-selective antagonists. Efficacy was achieved at doses that had no significant effects on motor activity. These results further confirm the therapeutic potential of CB2 receptor-selective agonists for the treatment of pain. In addition, they demonstrate that A-796260 may be a useful new pharmacol. compound for further studying CB2 receptor pharmacol. and for evaluating its role in the modulation of pain.
IT 666260-75-9
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in vitro and in vivo characterization of A-796260 and selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models)
RN 666260-75-9 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RE.CNT 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:1278230 CAPLUS
DN 147:496389
TI Use of CBx cannabinoid receptor modulators as potassium channel modulators, and therapeutic use thereof
IN Antel, Jochen; Gregory, Peter-Colin; Lange, Josephus Hubertus Maria; Firnges, Michael; Reiche, Dania
PA Solvay Pharmaceuticals GmbH, Germany
SO PCT Int. Appl., 62pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007125049	A1	20071108	WO 2007-EP53915	20070420
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI EP 2006-113190	A	20060427		
US 2006-745757P	T0	20060427		

AB The invention is discloses the use of at least one CBx modulator wherein the CBx modulator is selected from the group consisting of CB1 agonists; CB2 agonists; CB2 partial agonists; CB2 antagonists; CB2 inverse agonists; and dually acting compds. which are both a CB1 agonist and a CB2 agonist; and mixts. thereof, as KATP channel modulator for the prophylaxis, treatment, delayed progression, delayed onset and/or inhibition of a variety of disease conditions including obesity, diabetes mellitus, metabolic syndrome, syndrome X, insulinoma, familial hyperinsulemic hypoglycemia, male pattern baldness, detrusor hyperreactivity, asthma, neuroprotection, epilepsy, analgesia, cardioprotection, angina, cardioplegia, arrhythmia, coronary spasm, peripheral vascular disease, cerebral vasospasm, appetite regulation, neurodegeneration, pain (including neuropathic pain and chronic pain), and impotence in mammals and humans. The invention further discloses methods for treating, preventing, delaying progression of, delaying onset of and/or inhibiting a variety of disease conditions including obesity, diabetes mellitus, metabolic syndrome, syndrome X, insulinoma, familial hyperinsulemic hypoglycemia, male pattern baldness, detrusor hyperreactivity, asthma, neuroprotection, epilepsy, analgesia, cardioprotection, angina, cardioplegia, arrhythmia, coronary spasm, peripheral vascular disease, cerebral vasospasm, appetite regulation, neurodegeneration, pain (including neuropathic pain and chronic pain), and impotence in mammals and humans comprising administering to a subject in need thereof an effective amount of at least one CBx modulator having KATP channel modulating properties.
IT 666260-75-9, GW 842166X
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)
(CBx cannabinoid receptor modulators as potassium channel modulators, and therapeutic use)

RN 666260-75-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:1243322 CAPLUS
DN 147:491671
TI Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators
IN Antel, Jochen; Gregory, Peter-Colin; Lange, Josephus Hubertus Maria; Firnges, Michael; Reiche, Dania
PA Germany
SO U.S. Pat. Appl. Publ., 71pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20070254862	A1	20071101	US 2007-796716	20070426
US 20070254863	A1	20071101	US 2007-796740	20070426
PRAI US 2006-745757P	P	20060427		
US 2006-745760P	P	20060427		

AB Described herein are pharmaceutical compns. comprising therapeutically effective quantities of (i) a KATP channel modulator; and (ii) a CBx modulator. Also described herein are methods of making and using these compns. Thus, capsules comprising a KATP channel modulator and a CBx modulator comprised: 4-Chloro-N-[[3-(4-chlorophenyl)-4-phenyl-4,5-dihydropyrazol-1-yl]methylaminomethylene]benzenesulfonamide 50 mg, 3-(1,1-dimethylbutyl)-6,6,9-trimethyl-6a,7,10,10a-tetrahydro-6H-benzo[c]chromene (JW133) 50 mg, corn starch 150 mg, lactose 150 mg, and Et acetate q.s.
IT 666260-75-9, GW842166X
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical compns. comprising cbx cannabinoid receptor modulators and potassium channel modulators)
RN 666260-75-9 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



L4 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:484688 CAPLUS
DN 147:132884
TI Discovery of 2-[(2,4-Dichlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a Selective CB2 Receptor Agonist for the Treatment of Inflammatory Pain
AU Giblin, Gerard M. P.; O'Shaughnessy, Celestine T.; Naylor, Alan; Mitchell, William L.; Eatherton, Andrew J.; Slingsby, Brian P.; Rawlings, D. Anthony; Goldsmith, Paul; Brown, Andrew J.; Haslam, Carl P.; Clayton, Nick M.; Wilson, Alex W.; Chessell, Iain P.; Wittington, Andrew R.; Green, Richard
CS Neurology and GI Centre of Excellence for Drug Discovery, Molecular Discovery Research, GlaxoSmithKline, Harlow, Essex, CM19 5AW, UK
SO Journal of Medicinal Chemistry (2007), 50(11), 2597-2600
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
OS CASREACT 147:132884
AB Selective CB2 receptor agonists are promising potential therapeutic agents for the treatment of inflammatory and neuropathic pain. A focused screen identified a pyrimidine ester as a partial agonist at the CB2 receptor with micromolar potency. Subsequent lead optimization identified 35, GW842166X,(I) as the optimal compound in the series. 35 Has an oral ED50 of 0.1 mg/kg in the rat FCA model of inflammatory pain and was selected as a clin. candidate for this indication.
IT 666260-63-5P 666260-74-8P 666260-75-9P
666260-77-1P 666260-78-2P 666260-99-7P
666261-00-3P 666261-45-6P 666261-46-7P
666261-54-7P 666262-74-4P 666262-75-5P
666262-76-6P 666262-95-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Discovery of 2-[(2,4-Dichlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a Selective CB2 Receptor Agonist for the Treatment of Inflammatory Pain)
RN 666260-63-5 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666260-74-8 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,3-dichlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666260-75-9 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666260-77-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,5-dichlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666260-78-2 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3,5-dichlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666260-99-7 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,6-dichlorophenyl)amino]-N-[(tetrahydro-2H-

pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666261-00-3 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3,4-dichlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666261-45-6 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,4-difluorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666261-46-7 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(4-chloro-2-fluorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666261-54-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(2,3-difluorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-74-4 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chloro-2-fluorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-75-5 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(5-chloro-2-fluorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-76-6 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3,5-difluorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-95-9 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2-chloro-4-fluorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:823578 CAPLUS
DN 143:229872
TI Preparation of aminopyri(mi)dinecarboxamide CB2 modulators for use in combination with PDE4 inhibitors for treating pain, immune, inflammatory and rheumatic diseases
IN Green, Richard Howard; Brown, Andrew James; Connor, Helen Elizabeth; Eatherton, Andrew John; Giblin, Gerard Martin Paul; Jandu, Karamjit Singh; Knowles, Richard Graham; Mitchell, William Leonard; Naylor, Alan; O'Shaughnessy, Celestine Theresa; Palombi, Giovanni; Rawlings, Derek Anthony; Slingsby, Brian Peter; Tralau-Stewart, Catherine Jane; Whittington, Andrew Richard; Williamson, Richard Alexander
PA Glaxo Group Limited, UK; Doughty, Jennifer Margaret
SO PCT Int. Appl., 192 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005074939	A1	20050818	WO 2005-GB348	20050201
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1732561	A1	20061220	EP 2005-702088	20050201
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV				
	JP 2007520538	T	20070726	JP 2006-551906	20050201
	US 20080132505	A1	20080605	US 2006-597527 **ODP**	20061102
PRAI	GB 2004-2355	A	20040203		
	WO 2005-GB348	W	20050201		

OS CASREACT 143:229872; MARPAT 143:229872
AB The invention is related to combination of one or more CB2 modulators of formula I [X = CH, N; Y = (un)substituted Ph; R1 = H, cyclo/alkyl, (un)substituted haloalkyl; R2 = C(R7)2R3; R3 = (un)substituted non-aromatic heterocyclyl, cycloalk(en)yl, 5-6 membered aromatic heterocyclyl, etc.; R4 = H, COMe, SO2Me, cyclo/alkyl, (un)substituted haloalkyl; R6 = Me, Cl, CHmFn; n = 1-3; m = 0-2; (n + m) = 3; R7 = H, alkyl; when X = CH, R6 = Cl, or (un)substituted alkyl and R10 = H, or R10 = Cl, or (un)substituted alkyl and R10 = H; and their pharmaceutically acceptable salts] and one or more PDE4 inhibitors useful for treating conditions which are mediated by the activity of CB2 receptors or conditions which are mediated by PDE4, such as an immune disorder, an inflammatory disorder, pain, rheumatoid. The invention is also related to the preparation of CB2 modulators I. For example, reacting cyclobutylamine with 6-(2,3-dichlorophenylamino)-4-trifluoromethylnicotinic acid (preparation given) gave II in 81% yield. Selected I had EC50 values of >300 nM but <1000 nM and efficacy value of >50% at the cloned human cannabinoid CB2 receptor. Three formulations are given.

IT 666260-63-5P, 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666260-72-6P, 2-(3-Fluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666260-73-7P, 2-(3-Bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666260-74-8P, 2-(2,3-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666260-75-9P, 2-(2,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666260-77-1P, 2-(2,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666260-78-2P, 2-(3,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666260-99-7P, 2-(2,6-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666261-00-3P, 2-(3,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666261-33-2P, 2-[(3-Bromophenyl)amino]-4-(trifluoromethyl)pyrimidine-5-carboxylic acid [(4-hydroxytetrahydropyran-4-yl)methyl]amide 666261-45-6P, 2-[(2,4-Difluorophenyl)amino]-4-(trifluoromethyl)pyrimidine-5-carboxylicacid[(tetrahydropyran-4-yl)methyl]amide 666261-46-7P, 2-[(4-Chloro-2-fluorophenyl)amino]-4-(trifluoromethyl)pyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666261-51-4P, 2-[[4-Chloro-2-(trifluoromethyl)phenyl]amino]-4-(trifluoromethyl)pyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666261-54-7P, 2-[(2,3-Difluorophenyl)amino]-4-(trifluoromethyl)pyrimidine-5-carboxylicacid[(tetrahydropyran-4-yl)methyl]amide 666261-55-8P, 2-[(5-Chloro-2-methylphenyl)amino]-4-(trifluoromethyl)pyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666261-56-9P, 2-[(3-Chloro-2-cyanophenyl)amino]-4-(trifluoromethyl)pyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666261-57-0P, 2-[(2-Chloro-4-methylphenyl)amino]-4-(trifluoromethyl)pyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666261-58-1P, 2-[(4-Chloro-3-cyanophenyl)amino]-4-(trifluoromethyl)pyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666261-59-2P, 2-[(4-Chloro-2-methylphenyl)amino]-4-(trifluoromethyl)pyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666261-60-5P, 2-[(2-Chloro-5-methylphenyl)amino]-4-(trifluoromethyl)pyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666261-74-1P, 2-[(3-Chlorophenyl)amino]-4-(trifluoromethyl)pyrimidine-5-carboxylic acid [(4-hydroxytetrahydropyran-4-yl)methyl]amide 666261-75-2P, 2-[(3-Fluorophenyl)amino]-4-(trifluoromethyl)pyrimidine-5-carboxylic acid [(4-hydroxytetrahydropyran-4-yl)methyl]amide 666262-06-2P, 2-[(3-Chloro-2,6-dimethylphenyl)amino]-4-(trifluoromethyl)pyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666262-07-3P, 2-[(2-Chloro-6-methylphenyl)amino]-4-(trifluoromethyl)pyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666262-08-4P, 2-[(2-Chloro-3-methylphenyl)amino]-4-(trifluoromethyl)pyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666262-09-5P, 2-[(4-Chloro-2,6-dimethylphenyl)amino]-4-(trifluoromethyl)pyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666262-10-8P, 2-[[2-(Aminosulfonyl)-5-chlorophenyl]amino]-4-(trifluoromethyl)pyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666262-13-1P, 2-[[4-Fluoro-2-(trifluoromethyl)phenyl]amino]-4-(trifluoromethyl)pyrimidine-5-carboxylic

acid [(tetrahydropyran-4-yl)methyl]amide 666262-14-2P,
2-[[2-Fluoro-4-(trifluoromethyl)phenyl]amino]-4-
(trifluoromethyl)pyrimidine-5-carboxylic acid [(tetrahydropyran-4-
yl)methyl]amide 666262-35-7P, 2-[[3-Bromo-5-
(trifluoromethyl)phenyl]amino]-4-trifluoromethylpyrimidine-5-carboxylic
acid [(tetrahydropyran-4-yl)methyl]amide 666262-36-8P,
2-[[3-Fluoro-5-(trifluoromethyl)phenyl]amino]-4-trifluoromethylpyrimidine-
5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666262-37-9P
, 2-[[2-Fluoro-3-(trifluoromethyl)phenyl]amino]-4-
trifluoromethylpyrimidine-5-carboxylic acid [(tetrahydropyran-4-
yl)methyl]amide 666262-41-5P, 2-(3-Chloro-4-methylphenylamino)-4-
trifluoromethylpyrimidine-5-carboxylic acid [(tetrahydropyran-4-
yl)methyl]amide 666262-42-6P, 2-(3-Chloro-2-methylphenylamino)-4-
trifluoromethylpyrimidine-5-carboxylic acid [(tetrahydropyran-4-
yl)methyl]amide 666262-43-7P, 2-[(4-Chloro-3-
methoxyphenyl)amino]-4-trifluoromethylpyrimidine-5-carboxylic acid
[(tetrahydropyran-4-yl)methyl]amide 666262-44-8P,
2-(4-Chloro-3-methylphenylamino)-4-trifluoromethylpyrimidine-5-carboxylic
acid [(tetrahydropyran-4-yl)methyl]amide 666262-74-4P,
2-(2-Fluoro-3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic
acid [(tetrahydropyran-4-yl)methyl]amide 666262-75-5P,
2-(2-Fluoro-5-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic
acid [(tetrahydropyran-4-yl)methyl]amide 666262-76-6P,
2-(3,5-Difluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid
[(tetrahydropyran-4-yl)methyl]amide 666262-77-7P,
2-(4-Fluoro-3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic
acid [(tetrahydropyran-4-yl)methyl]amide 666262-78-8P,
2-(4-Trifluoromethoxy-3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-
carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666262-79-9P
, 2-(4-Cyano-3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-
carboxylicacid[(tetrahydropyran-4-yl)methyl]amide 666262-80-2P,
2-(4-Trifluoromethyl-3-fluorophenylamino)-4-trifluoromethylpyrimidine-5-
carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666262-94-8P
, 2-(2-Fluoro-4-bromophenylamino)-4-trifluoromethylpyrimidine-5-
carboxylicacid[(tetrahydropyran-4-yl)methyl]amide 666262-95-9P,
2-(2-Chloro-4-fluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic
acid [(tetrahydropyran-4-yl)methyl]amide 666262-96-0P,
2-(2-Chloro-4-bromophenylamino)-4-trifluoromethylpyrimidine-5-
carboxylicacid[(tetrahydropyran-4-yl)methyl]amide 666262-97-1P,
2-(2-Chloro-4-cyanophenylamino)-4-trifluoromethylpyrimidine-5-
carboxylicacid[(tetrahydropyran-4-yl)methyl]amide 666262-98-2P,
2-(2-Chloro-4-trifluoromethylphenylamino)-4-trifluoromethylpyrimidine-5-
carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666263-01-0P
, 2-(2-Bromo-4-chlorophenylamino)-4-trifluoromethylpyrimidine-5-
carboxylicacid[(tetrahydropyran-4-yl)methyl]amide 666263-15-6P,
2-(2-Trifluoromethyl-4-bromophenylamino)-4-trifluoromethylpyrimidine-5-
carboxylic acid [(tetrahydropyran-4-yl)methyl]amide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(drug candidate; preparation of aminopyri(mi)dinecarboxamide CB2 modulators
for use in combination with PDE4 inhibitors for treating pain, immune,
inflammatory and rheumatic diseases)

RN 666260-63-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[(tetrahydro-2H-pyran-
4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666260-72-6 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-fluorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666260-73-7 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-bromophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666260-74-8 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,3-dichlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666260-75-9 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



compound claimed in 10/524,470

RN 666260-77-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,5-dichlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666260-78-2 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3,5-dichlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666260-99-7 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,6-dichlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666261-00-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(3,4-dichlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666261-33-2 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-bromophenyl)amino]-N-[(tetrahydro-4-hydroxy-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666261-45-6 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,4-difluorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666261-46-7 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(4-chloro-2-fluorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666261-51-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-chloro-2-(trifluoromethyl)phenyl]amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666261-54-7 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,3-difluorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666261-55-8 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(5-chloro-2-methylphenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666261-56-9 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chloro-2-cyanophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666261-57-0 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2-chloro-4-methylphenyl)amino]-N-[(tetrahydro-

2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666261-58-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(4-chloro-3-cyanophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666261-59-2 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(4-chloro-2-methylphenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666261-60-5 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2-chloro-5-methylphenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666261-74-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[(tetrahydro-4-hydroxy-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666261-75-2 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-fluorophenyl)amino]-N-[(tetrahydro-4-hydroxy-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-06-2 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chloro-2,6-dimethylphenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-07-3 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2-chloro-6-methylphenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-08-4 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2-chloro-3-methylphenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-09-5 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(4-chloro-2,6-dimethylphenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-10-8 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[[2-(aminosulfonyl)-5-chlorophenyl]amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-13-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[[4-fluoro-2-(trifluoromethyl)phenyl]amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-14-2 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[[2-fluoro-4-(trifluoromethyl)phenyl]amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-35-7 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[[3-bromo-5-(trifluoromethyl)phenyl]amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-36-8 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[[3-fluoro-5-(trifluoromethyl)phenyl]amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-37-9 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[[2-fluoro-3-(trifluoromethyl)phenyl]amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-41-5 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chloro-4-methylphenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-42-6 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chloro-2-methylphenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-43-7 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(4-chloro-3-methoxyphenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-44-8 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(4-chloro-3-methylphenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-74-4 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chloro-2-fluorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-75-5 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(5-chloro-2-fluorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-76-6 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3,5-difluorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-77-7 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chloro-4-fluorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-78-8 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[[3-chloro-4-(trifluoromethoxy)phenyl]amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-79-9 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chloro-4-cyanophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-80-2 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[[3-fluoro-4-(trifluoromethyl)phenyl]amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-94-8 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(4-bromo-2-fluorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-95-9 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2-chloro-4-fluorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-96-0 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(4-bromo-2-chlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-97-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2-chloro-4-cyanophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-98-2 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[[2-chloro-4-(trifluoromethyl)phenyl]amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666263-01-0 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2-bromo-4-chlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666263-15-6 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[[4-bromo-2-(trifluoromethyl)phenyl]amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:182848 CAPLUS
DN 140:217658
TI Preparation of aminopyrimidinecarboxamides and their use as CB2-type cannabinoid receptor modulators
IN Eatherton, Andrew John; Giblin, Gerard Martin Paul; Green, Richard Howard; Mitchell, William Leonard; Naylor, Alan; Rawlings, Derek Anthony; Slingsby, Brian Peter; Whittington, Andrew Richard
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 129 pp.
CODEN: PIXXD2
DT Patent
LA English

Applicant's

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004018433	A1	20040304	WO 2003-EP9217	20030819
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2495880	A1	20040304	CA 2003-2495880	20030819
	AU 2003264076	A1	20040311	AU 2003-264076	20030819
	AU 2003264076	B2	20070920		
	EP 1539712	A1	20050615	EP 2003-792388	20030819
	EP 1539712	B1	20071107		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003013676	A	20050621	BR 2003-13676	20030819
	JP 2006501228	T	20060112	JP 2004-530220	20030819
	US 20060293354	A1	20061228	US 2003-524470	20030819
	NZ 537886	A	20070531	NZ 2003-537886	20030819
	AT 377591	T	20071115	AT 2003-792388	20030819
	EP 1878725	A2	20080116	EP 2007-119063	20030819
	EP 1878725	A3	20080130		
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR, LT, LV				
	ES 2295682	T3	20080416	ES 2003-792388	20030819
	ZA 2005000913	A	20060726	ZA 2005-913	20050201
	MX 2005PA01960	A	20050428	MX 2005-PA1960	20050218
	NO 2005001451	A	20050318	NO 2005-1451	20050318
	HK 1079193	A1	20080425	HK 2005-110876	20051129
	AU 2007211954	A1	20070913	AU 2007-211954	20070827
	IN 2007DN09023	A	20080208	IN 2007-DN9023	20071122
PRAI	GB 2002-19501	A	20020821		
	GB 2003-9326	A	20030424		
	AU 2003-264076	A3	20030819		
	EP 2003-792388	A3	20030819		
	WO 2003-EP9217	W	20030819		
	IN 2005-DN295	A3	20050125		

OS MARPAT 140:217658

AB This invention relates to novel aminopyrimidinecarboxamides (shown as I; variables defined below; e.g. II), pharmaceutical compns. containing these compds., particularly in nanoparticulate form for increased bioavailability (no data), and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor. For I: Y is Ph, (un)substituted with 1-3 substituents; R1 = H, C1-6 alkyl, C3-6 cycloalkyl and halo-substituted C1-6 alkyl; R2 is (CH2)mR3 where m = 0-1; or R1 and R2 together with N to which they are attached form an (un)substituted 4-8-membered nonarom. heterocyclyl ring; R3 is an (un)substituted 4-8-membered nonarom. heterocyclyl, an (un)substituted C3-8 cycloalkyl, an (un)substituted straight or branched C1-10 alkyl, a C5-7 cycloalkenyl or R5; R4 = H, C1-6 alkyl, C3-6 cycloalkyl, or halo-substituted C1-6 alkyl, COCH3, and SO2Me; R5 is III wherein p = 0-2 and X is CH2 or O; R6 is Me, chloro or CHxFn wherein n = 1-3, x = 0-2 and n and x add up to 3; R7 is OH, C1-6-alkoxy, NR8aR8b, NHCOR9, NHSO2R9, SOqR9; R8a is H or C1-6alkyl; R8b is H or C1-6alkyl; R9 is C1-6alkyl; q is 0-2. Although the methods of preparation are not claimed, .apprx.265 example prepns. are included. For example, 2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid benzylamide was prepared in 3 steps starting substitution of benzyl 2-chloro-4-trifluoromethylpyrimidine-5-carboxylate by 3-chloroaniline to give benzyl 2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylate followed by base hydrolysis to give 2-(3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid followed by amide formation with benzylamine. The example compds. had EC50 values >2000 nM and/or efficacy values of <50% at the cloned human cannabinoid CB1 receptor; some of the example compds., e.g. II, had EC50 values 20-300 nM and efficacy values >50% at the cloned human cannabinoid CB2 receptor. Particle size analyses were carried out on 7 examples of I pre- and post-milling, e.g. 13.15 and 0.33 μM, resp., for 2-(4-cyanophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid (cyclopentylmethyl)amide.

IT 666260-63-5P, 2-(3-Chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666260-72-6P, 2-(3-Fluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666260-73-7P, 2-(3-Bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666260-74-8P, 2-(2,3-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666260-75-9P, 2-(2,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666260-77-1P, 2-(2,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666260-78-2P, 2-(3,5-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666260-99-7P, 2-(2,6-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666261-00-3P, 2-(3,4-Dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666261-33-2P, 2-[(3-Bromophenyl)amino]-4-(trifluoromethyl)pyrimidine-5-carboxylic acid [(4-hydroxytetrahydropyran-4-yl)methyl]amide 666261-45-6P, 2-[(2,4-Difluorophenyl)amino]-4-(trifluoromethyl)pyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666261-46-7P, 2-[(4-Chloro-2-fluorophenyl)amino]-4-(trifluoromethyl)pyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666261-51-4P, 2-[[4-Chloro-2-(trifluoromethyl)phenyl]amino]-4-

(trifluoromethyl)pyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666261-54-7P, 2-[(2,3-Difluorophenyl)amino]-4-(trifluoromethyl)pyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666261-55-8P, 2-[(5-Chloro-2-methylphenyl)amino]-4-(trifluoromethyl)pyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666261-56-9P, 2-[(3-Chloro-2-cyanophenyl)amino]-4-(trifluoromethyl)pyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666261-57-0P, 2-[(2-Chloro-4-methylphenyl)amino]-4-(trifluoromethyl)pyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666261-58-1P, 2-[(4-Chloro-3-cyanophenyl)amino]-4-(trifluoromethyl)pyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666261-59-2P, 2-[(4-Chloro-2-methylphenyl)amino]-4-(trifluoromethyl)pyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666261-60-5P, 2-[(2-Chloro-5-methylphenyl)amino]-4-(trifluoromethyl)pyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666261-74-1P, 2-[(3-Chlorophenyl)amino]-4-(trifluoromethyl)pyrimidine-5-carboxylic acid [(4-hydroxytetrahydropyran-4-yl)methyl]amide 666261-75-2P, 2-[(3-Fluorophenyl)amino]-4-(trifluoromethyl)pyrimidine-5-carboxylic acid [(4-hydroxytetrahydropyran-4-yl)methyl]amide 666262-06-2P, 2-[(3-Chloro-2,6-dimethylphenyl)amino]-4-(trifluoromethyl)pyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666262-07-3P, 2-[(2-Chloro-6-methylphenyl)amino]-4-(trifluoromethyl)pyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666262-08-4P , 2-[(2-Chloro-3-methylphenyl)amino]-4-(trifluoromethyl)pyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666262-09-5P , 2-[(4-Chloro-2,6-dimethylphenyl)amino]-4-(trifluoromethyl)pyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666262-10-8P , 2-[[2-(Aminosulfonyl)-5-chlorophenyl]amino]-4-(trifluoromethyl)pyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666262-13-1P, 2-[[4-Fluoro-2-(trifluoromethyl)phenyl]amino]-4-(trifluoromethyl)pyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666262-14-2P, 2-[[2-Fluoro-4-(trifluoromethyl)phenyl]amino]-4-(trifluoromethyl)pyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666262-35-7P, 2-[[3-Bromo-5-(trifluoromethyl)phenyl]amino]-4-trifluoromethylpyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666262-36-8P, 2-[[3-Fluoro-5-(trifluoromethyl)phenyl]amino]-4-trifluoromethylpyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666262-37-9P , 2-[[2-Fluoro-3-(trifluoromethyl)phenyl]amino]-4-trifluoromethylpyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666262-41-5P, 2-(3-Chloro-4-methylphenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666262-42-6P, 2-(3-Chloro-2-methylphenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666262-43-7P, 2-[(4-Chloro-3-methoxyphenyl)amino]-4-trifluoromethylpyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666262-44-8P, 2-(4-Chloro-3-methylphenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666262-74-4P, 2-(2-Fluoro-3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666262-75-5P, 2-(2-Fluoro-5-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666262-76-6P, 2-(3,5-Difluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666262-77-7P,

2-(4-Fluoro-3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666262-78-8P, 2-(4-Trifluoromethoxy-3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666262-79-9P, 2-(4-Cyano-3-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666262-80-2P, 2-(4-Trifluoromethyl-3-fluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666262-94-8P, 2-(2-Fluoro-4-bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666262-95-9P, 2-(2-Chloro-4-fluorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666262-96-0P, 2-(2-Chloro-4-bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666262-97-1P, 2-(2-Chloro-4-cyanophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666262-98-2P, 2-(2-Chloro-4-trifluoromethylphenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666263-01-0P, 2-(2-Bromo-4-chlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide 666263-15-6P, 2-(2-Trifluoromethyl-4-bromophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid [(tetrahydropyran-4-yl)methyl]amide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of aminopyrimidinecarboxamides and their use as CB2-type cannabinoid receptor modulators)

RN 666260-63-5 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666260-72-6 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-fluorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666260-73-7 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-bromophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666260-74-8 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,3-dichlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666260-75-9 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666260-77-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,5-dichlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666260-78-2 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3,5-dichlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666260-99-7 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,6-dichlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666261-00-3 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3,4-dichlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666261-33-2 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-bromophenyl)amino]-N-[(tetrahydro-4-hydroxy-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666261-45-6 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,4-difluorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666261-46-7 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(4-chloro-2-fluorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666261-51-4 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[[4-chloro-2-(trifluoromethyl)phenyl]amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666261-54-7 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2,3-difluorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666261-55-8 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(5-chloro-2-methylphenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666261-56-9 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chloro-2-cyanophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666261-57-0 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2-chloro-4-methylphenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666261-58-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(4-chloro-3-cyanophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666261-59-2 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(4-chloro-2-methylphenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666261-60-5 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2-chloro-5-methylphenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666261-74-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)amino]-N-[(tetrahydro-4-hydroxy-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666261-75-2 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-fluorophenyl)amino]-N-[(tetrahydro-4-hydroxy-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-06-2 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chloro-2,6-dimethylphenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-07-3 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2-chloro-6-methylphenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-08-4 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2-chloro-3-methylphenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-09-5 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(4-chloro-2,6-dimethylphenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-10-8 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[[2-(aminosulfonyl)-5-chlorophenyl]amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-13-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[[4-fluoro-2-(trifluoromethyl)phenyl]amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-14-2 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[[2-fluoro-4-(trifluoromethyl)phenyl]amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-35-7 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[[3-bromo-5-(trifluoromethyl)phenyl]amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-36-8 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[[3-fluoro-5-(trifluoromethyl)phenyl]amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-37-9 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[[2-fluoro-3-(trifluoromethyl)phenyl]amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-41-5 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chloro-4-methylphenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-42-6 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chloro-2-methylphenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-43-7 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(4-chloro-3-methoxyphenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-44-8 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(4-chloro-3-methylphenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-74-4 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chloro-2-fluorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-75-5 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(5-chloro-2-fluorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-76-6 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3,5-difluorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-77-7 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chloro-4-fluorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-78-8 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[[3-chloro-4-(trifluoromethoxy)phenyl]amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-79-9 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(3-chloro-4-cyanophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-80-2 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[[3-fluoro-4-(trifluoromethyl)phenyl]amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-94-8 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(4-bromo-2-fluorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-95-9 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2-chloro-4-fluorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-96-0 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(4-bromo-2-chlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-97-1 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2-chloro-4-cyanophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666262-98-2 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[[2-chloro-4-(trifluoromethyl)phenyl]amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666263-01-0 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[(2-bromo-4-chlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 666263-15-6 CAPLUS
CN 5-Pyrimidinecarboxamide, 2-[[4-bromo-2-(trifluoromethyl)phenyl]amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      45.04     224.07

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -6.40      -6.40

STN INTERNATIONAL LOGOFF AT 18:13:15 ON 28 SEP 2008
```